文献速递眼底病与葡萄膜炎神经眼科

免疫检查点调控能否重新定义眼免疫治疗?新兴机制、挑战与转化机遇——综合综述

Can Immune Checkpoint Modulation Redefine Ocular Immunotherapy? Emerging Mechanisms, Challenges, and Translational Opportunities-A Comprehensive Review.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

免疫检查点抑制剂已革新肿瘤免疫治疗,其应用正扩展至葡萄膜黑色素瘤、自身免疫性葡萄膜炎和表面鳞状肿瘤等眼部疾病。综述梳理PD-1、CTLA-4、TIM-3、LAG-3、CEACAM1等关键调控分子及T细胞耗竭(Tex)机制,汇总临床前小鼠模型中PD-1抑制剂联合OX40/CD137激动剂及TIM-3与PD-1双阻断的策略,并提出未来应开发IL-10/TGF-β促进疗法以减少免疫相关不良事件、验证LAG-3+肿瘤浸润淋巴细胞作为葡萄膜黑色素瘤疗效生物标志物。

要点

  • 眼部免疫豁免使葡萄膜黑色素瘤等疾病诊断时多已晚期,免疫检查点调控成为潜在新策略。
  • 临床前小鼠模型中,PD-1抑制剂联合OX40或CD137激动剂、TIM-3与PD-1双阻断可增强T细胞应答。
  • 未来研究应开发IL-10/TGF-β促进疗法以减轻视网膜血管炎等免疫相关不良事件。

核心结论

  • 免疫检查点疗法有潜力改变眼部疾病管理,为既往选择有限的患者提供创新治疗选择,但需探索有效联合方案、最佳使用时机及更好的患者选择标准。

研究设计与样本

  • 综合综述,聚焦免疫检查点在眼部疾病中的机制、挑战与转化机遇。

主要发现

  • PD-1、CTLA-4、TIM-3、LAG-3和CEACAM1是调节眼部免疫应答的关键调控分子。
  • T细胞耗竭(Tex)因长期抗原暴露导致免疫功能障碍,是眼部免疫治疗的重要障碍。
  • 临床前小鼠模型中,PD-1抑制剂联合OX40或CD137等共刺激激动剂的联合治疗显示出应用前景。
  • 靶向TIM-3联合PD-1的双重阻断可增强T细胞应答。
  • 靶向多条通路的整合策略可能在免疫失调性眼病中带来更好疗效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出眼部免疫检查点治疗优化仍面临多项挑战。
  • 原文指出需探索检查点抑制剂的有效联合、确定最佳使用时机并建立更好的患者选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors have revolutionized cancer immunotherapy, and their application is now expanding to various conditions, including prevalent medical issues such as uveal melanoma, autoimmune uveitis, and surface squamous neoplasms. The unique immunological challenges in these cases arise from the immune-privileged nature of the eye, which employs immune evasion mechanisms that often lead to an advanced disease at diagnosis. Recent breakthroughs in immune checkpoints have identified critical regulatory molecules, such as PD-1, CTLA-4, TIM-3, LAG-3, and CEACAM1, which are pivotal in modulating ocular immune responses. The use of novel immunotherapeutic strategies to block these pathways presents new opportunities to treat ocular and inflammatory eye disorders. T-cell exhaustion (Tex) is a significant hurdle in ocular immunotherapy that results in immune dysfunction because of prolonged antigen exposure. Strategies to counteract Tex, including combination therapies that pair PD-1 inhibitors with co-stimulatory agonists such as OX40 and CD137, have shown promise in preclinical murine models. Additionally, dual blockade targeting TIM-3 alongside PD-1 has been found to enhance T-cell responses. An integrated approach targeting multiple pathways may yield improved therapeutic outcomes in eye diseases characterized by immune dysregulation. However, several challenges remain in optimizing immune checkpoint therapies for ocular conditions. Future research should prioritize dual objectives: (1) developing IL-10/TGF-β-promoting therapies to mitigate immune-related adverse events (e.g., retinal vasculitis) and (2) validating LAG-3 + tumor-infiltrating lymphocytes as biomarkers for predicting immune checkpoint inhibitor response in uveal melanoma. It is essential to explore effective combinations of checkpoint inhibitors, determine the optimal timing for their use, and establish better criteria for patient selection. As research on immune checkpoint therapies progresses, they have the potential to transform the management of ocular diseases, offering innovative treatment options for patients who previously had limited choices.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Chen KY, Chan HC, Chan CM, et al. Can Immune Checkpoint Modulation Redefine Ocular Immunotherapy? Emerging Mechanisms, Challenges, and Translational Opportunities-A Comprehensive Review. Invest Ophthalmol Vis Sci. 2025. PMID: 41268982. doi:10.1167/iovs.66.14.53

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。